CNS Pharmaceuticals(CNSP)
$4.44+0.29 (+6.99%)
CNSP
CNS Pharmaceuticals financials statements
$4.44
At close:+0.29 (+6.99%)
Want to see CNSP full AI Analyst Report?
CNS Pharmaceuticals (CNSP) Ratios
1,099 Followers
CNS Pharmaceuticals Ratios
CNSP's free cash flow for Q3 2026 was $-2.77M. For the 2026 fiscal year, CNSP's free cash flow was increased by $0.00 and operating cash flow was $-2.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.98 | 3.43 | 0.26 | 2.55 | 3.50 |
| Quick Ratio | 1.98 | 3.43 | 0.26 | 2.55 | 3.50 |
| Cash Ratio | 1.76 | 2.56 | 0.09 | 2.04 | 2.34 |
| Solvency Ratio | -3.86 | -5.88 | -3.07 | -3.10 | -6.78 |
| Operating Cash Flow Ratio | -3.37 | -6.78 | -2.31 | -2.15 | -6.34 |
| Short-Term Operating Cash Flow Coverage | -42.03 | -52.48 | -47.01 | -25.75 | -34.91 |
| Net Current Asset Value | $ 4.00M | $ 6.13M | $ -4.54M | $ 7.64M | $ 5.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.18 | 0.03 | 0.04 |
| Debt-to-Equity Ratio | 0.07 | 0.05 | -0.07 | 0.05 | 0.06 |
| Debt-to-Capital Ratio | 0.07 | 0.05 | -0.07 | 0.05 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.91 | 1.41 | -0.38 | 1.60 | 1.32 |
| Debt Service Coverage Ratio | -46.05 | -43.36 | -59.95 | -36.58 | -36.45 |
| Interest Coverage Ratio | -1049.68 | -924.50 | -1366.54 | -2125.08 | -1560.14 |
| Debt to Market Cap | 0.14 | 0.14 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.78 | 10.74 | 0.05 | 0.18 | 0.28 |
| Net Debt to EBITDA | 0.43 | 0.41 | 0.01 | 0.63 | 0.32 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.15% | 99.70% | 99.93% | 102.28% | 100.06% |
| Return on Assets (ROA) | -183.81% | -170.76% | -1108.34% | -117.02% | -165.52% |
| Return on Equity (ROE) | -350.48% | -240.55% | 425.33% | -187.81% | -218.90% |
| Return on Capital Employed (ROCE) | -353.49% | -241.26% | 425.65% | -183.61% | -218.76% |
| Return on Invested Capital (ROIC) | -329.54% | -229.17% | 456.64% | -174.80% | -206.66% |
| Return on Tangible Assets | -183.81% | -170.76% | -1108.34% | -117.02% | -165.52% |
| Earnings Yield | -680.96% | -645.69% | -0.01% | -0.01% | -0.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -242699.61 | -514934.48 | -114315.54 | -42527.19 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 242699.61 | 514934.48 | 114315.54 | 42527.19 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -31.15 | -537.26 | -2.27 | -4.67 | -9.59 |
| Free Cash Flow Per Share | -31.19 | -537.39 | -2.27 | -4.67 | -9.60 |
| Dividend Paid and CapEx Coverage Ratio | -759.90 | -4086.27 | -3624.72 | -2387.57 | -2355.31 |
| Capital Expenditure Coverage Ratio | -759.90 | -4086.27 | -3624.72 | -2387.57 | -2355.31 |
| Operating Cash Flow Coverage Ratio | -42.03 | -52.48 | -47.01 | -25.75 | -34.91 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -594.12% | -743.90% | -0.01% | -0.01% | -0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.15 | -0.15 | -12581.28 | -10655.68 | -61536.08 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.51 | 0.37 | -53512.26 | 20012.20 | 134702.83 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.17 | -0.13 | -16768.50 | -15409.27 | -65857.50 |
| Price-to-Operating Cash Flow Ratio | -0.17 | -0.13 | -16773.12 | -15415.72 | -65885.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 226.95 | -5.28 | 8768.89 |
| Enterprise Value Multiple | 0.29 | 0.26 | -12574.76 | -10668.17 | -61630.81 |
| Enterprise Value | -4.54M | -3.83M | 237.17B | 162.75B | 891.97B |
| EV to EBITDA | 0.29 | 0.26 | -12574.76 | -10668.17 | -61630.81 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.33 | 0.22 | -16768.48 | -15408.36 | -65857.16 |
| EV to Operating Cash Flow | 0.33 | 0.22 | -16773.11 | -15414.81 | -65885.12 |
| Tangible Book Value Per Share | 10.20 | 193.91 | -0.71 | 3.60 | 4.69 |
| Shareholders’ Equity Per Share | 10.20 | 193.91 | -0.71 | 3.60 | 4.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -35.75 | -466.45 | -3.03 | -6.76 | -10.27 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.87 | 1.15 | 0.75 | 0.69 | 0.93 |
Currency in USD

